摘要
目的观察参麦注射液联合阿美替尼治疗表皮生长因子受体(EGFR)突变晚期非小细胞肺癌(NSCLC)的疗效及安全性分析。方法选择2020年1月至2022年12月EGFR突变阳性晚期NSCLC患者60例,采用随机数字表法分为观察组与对照组,每组各30例。观察组给予参麦注射液联合阿美替尼治疗,对照组给予阿美替尼治疗。结果观察组客观缓解率(ORR)和疾病控制率(DCR)均高于对照组,差异有统计学意义(P<0.05)。观察组和对照组治疗后KPS功能状态评分均高于治疗前,且观察组治疗前后KPS评分差值(20.00±13.13)高于对照组(11.00±10.23),差异均有统计学意义(P<0.05)。观察组患者皮疹、白细胞减少、血小板减少发生率低于对照组,差异均有统计学意义(P<0.05)。结论阿美替尼联合参麦注射液治疗EGFR突变阳性晚期NSCLC患者,可改善患者ORR、DCR,提高患者生存质量,降低不良反应发生。
Objective To observe the efficacy and safety of Shenmai injection combined with amitinib in the treatment of advanced non-small cell lung cancer with EGFR mutation,and to explore the application value of this combined regimen.Methods Sixty patients with advanced NSCLC with positive EGFR mutation were enrolled in the Department of Respiratory and Critical Care and Department of Oncology,Affiliated Hospital of Hangzhou Normal University from January 2020 to December 2022.They were randomly divided into the observation group and the control group according to random number table method.Amitinib combined with Shenmai injection was observed and treated in the control group,with 30 patients in each group.Results The Objective Response rate(ORR)and Disease control rate(DCR)of the observation group were significantly higher than those of the control group(P<0.05).After the treatment,the KPS scores of the observation group and the control group were higher than those before the treatment(P<0.05),and the difference of KPS scores before and after the treatment showed that the treatment group(20.00±13.13)was significantly higher than that of the control group(11.00±10.23)(P<0.05).In terms of safety,the incidence of rash,leukopenia and thrombocytopenia in the observation group was significantly lower than that in the control group(P<0.05).Conclusion Amitinib combined with Shenmai injection can improve ORR and DCR of patients with advanced NSCLC with positive EGFR mutation,and improve their quality of life and reduce the occurrence of adverse reactions.
出处
《浙江临床医学》
2024年第4期523-524,共2页
Zhejiang Clinical Medical Journal
基金
杭州市生物医药和健康产业发展扶持科技专项(2021WJCY134)。
